Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
233.8
USD
-0.89%
-1.71%
+6.35%
United Therapeutics Corporation authorizes a Buyback Plan.
The Board of Directors of United Therapeutics Corporation has authorized a buyback plan on March 24, 2024.
United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing
Apr. 23
MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says
Apr. 23
MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing
Apr. 19
MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing
Apr. 17
MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing
Apr. 15
MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing
Apr. 11
MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing
Apr. 09
MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing
Apr. 05
MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing
Apr. 04
MT
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension
Apr. 01
MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling
Apr. 01
DJ
United Therapeutics Corporation Announces Extension of Credit Agreement
Mar. 29
CI
United Therapeutics Insider Sold Shares Worth $7,375,339, According to a Recent SEC Filing
Mar. 27
MT
United Therapeutics Corporation announces an Equity Buyback for $1,000 million worth of its shares.
Mar. 25
CI
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing
Mar. 25
MT
United Therapeutics Authorizes Accelerated $1 Billion Stock Buyback Through Citigroup
Mar. 25
MT
United Therapeutics Corporation authorizes a Buyback Plan.
Mar. 23
CI
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing
Mar. 22
MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing
Mar. 21
MT
United Therapeutics Insider Sold Shares Worth $7,209,192, According to a Recent SEC Filing
Mar. 15
MT
Transcript : United Therapeutics Corporation Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 01:40 PM
Mar. 12
United Therapeutics Insider Sold Shares Worth $7,232,241, According to a Recent SEC Filing
Mar. 11
MT
United Therapeutics Insider Sold Shares Worth $1,424,309, According to a Recent SEC Filing
Mar. 07
MT
United Therapeutics Insider Sold Shares Worth $3,705,423, According to a Recent SEC Filing
Mar. 05
MT
Transcript : United Therapeutics Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM
Mar. 05
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
More about the company
Last Close Price
233.8
USD
Average target price
285.5
USD
Spread / Average Target
+22.08%
Consensus
1st Jan change
Capi.
+6.35% 11B +1.51% 42.75B +8.57% 41.34B +49.22% 41.61B -12.36% 26.59B +8.92% 25.49B -25.13% 18.12B +29.17% 12.24B -3.12% 11.76B -16.98% 10.07B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
UNITED THERAPEUTICS CORPORATION 
